Small Pharma Inc. (CVE:DMT – Get Free Report) shares dropped 6.3% during trading on Tuesday . The company traded as low as C$0.15 and last traded at C$0.15. Approximately 1,890,765 shares changed hands during trading, an increase of 538% from the average daily volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Trading Down 6.3 %
The company has a 50 day simple moving average of C$0.15 and a two-hundred day simple moving average of C$0.15. The company has a debt-to-equity ratio of 5.95, a quick ratio of 6.28 and a current ratio of 2.63. The firm has a market cap of C$50.37 million, a PE ratio of -2.14 and a beta of 0.86.
Small Pharma Company Profile
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Featured Articles
- Five stocks we like better than Small Pharma
- When to Sell a Stock for Profit or Loss
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- 3 Stocks to Consider Buying in October
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- What Are Dividend Challengers?
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
